Condition: Decompensated Cirrhosis · Sponsor: Beijing 302 Hospital
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.
This description comes directly from the study's public registry record.
Lei Shi, MD,PhD · 86-10-66949623 · shilei302@126.com
Fu-Sheng Wang, MD,PhD · 86-10-66933332 · fswang302@163.com
Always discuss trial participation with your own doctor first.
| The First Hospital of Lanzhou University | Lanzhou, Gansu, China | Not Yet Recruiting |
| Third Affiliated Hospital, Sun Yat-Sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Hainan hospital of Chinese PLA General Hospital | Sanya, Hainan, China | Recruiting |
| Jin Yin-tan Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Shanghai Changzheng Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Xinjiang Kashi Area Number 1 Hospital | Kashgar, Xinjiang, China | Not Yet Recruiting |
| Beijing 302 Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05224960